MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.47 -0.36 (-2.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗
Amylyx (AMLX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗
Via Chartmill
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder ↗
Via Stocktwits
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million ↗
A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
Via The Motley Fool
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028 ↗
Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline. 
Via Chartmill
News headline image
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target ↗
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a... 
Via Stocktwits
News headline image
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial ↗
Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026. 
Via Benzinga
News headline image
Amylyx (AMLX) Q2 Net Loss Narrows 43% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted ↗
Amylyx Pharmaceuticals reports Q2 2025 earnings with EPS in line, $41.4M net loss. Market reaction muted as focus remains on clinical-stage pipeline updates. 
Via Chartmill
News headline image
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery ↗
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia. 
Via Benzinga
News headline image
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial ↗
The company is advancing the treatment into a Phase 3 study with results expected in 2026. 
Via Stocktwits
News headline image
Why Shares in Amylyx Pharmaceuticals Soared This Week ↗
Via The Motley Fool
News headline image
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market ↗
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity. 
Via Benzinga
News headline image
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story